vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PHOTRONICS INC (PLAB). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $210.4M, roughly 1.3× PHOTRONICS INC). PHOTRONICS INC runs the higher net margin — 10.9% vs -45.7%, a 56.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -5.5%). PHOTRONICS INC produced more free cash flow last quarter ($25.2M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -3.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.
GH vs PLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $210.4M |
| Net Profit | $-128.5M | $22.9M |
| Gross Margin | 64.6% | 33.7% |
| Operating Margin | -43.0% | 22.9% |
| Net Margin | -45.7% | 10.9% |
| Revenue YoY | 39.4% | -5.5% |
| Net Profit YoY | -15.8% | -32.4% |
| EPS (diluted) | $-1.01 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | — | ||
| Q3 25 | $265.2M | $210.4M | ||
| Q2 25 | $232.1M | $211.0M | ||
| Q1 25 | $203.5M | $212.1M | ||
| Q4 24 | $201.8M | $222.6M | ||
| Q3 24 | $191.5M | $211.0M | ||
| Q2 24 | $177.2M | $217.0M | ||
| Q1 24 | $168.5M | $216.3M |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $22.9M | ||
| Q2 25 | $-99.9M | $8.9M | ||
| Q1 25 | $-95.2M | $42.9M | ||
| Q4 24 | $-111.0M | $33.9M | ||
| Q3 24 | $-107.8M | $34.4M | ||
| Q2 24 | $-102.6M | $36.3M | ||
| Q1 24 | $-115.0M | $26.2M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | 33.7% | ||
| Q2 25 | 65.0% | 36.9% | ||
| Q1 25 | 63.3% | 35.6% | ||
| Q4 24 | 61.6% | 37.0% | ||
| Q3 24 | 61.1% | 35.6% | ||
| Q2 24 | 59.1% | 36.5% | ||
| Q1 24 | 61.2% | 36.6% |
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | 22.9% | ||
| Q2 25 | -45.9% | 26.4% | ||
| Q1 25 | -54.6% | 24.6% | ||
| Q4 24 | -62.4% | 25.1% | ||
| Q3 24 | -61.3% | 24.7% | ||
| Q2 24 | -56.8% | 25.8% | ||
| Q1 24 | -59.2% | 26.6% |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 10.9% | ||
| Q2 25 | -43.0% | 4.2% | ||
| Q1 25 | -46.8% | 20.2% | ||
| Q4 24 | -55.0% | 15.2% | ||
| Q3 24 | -56.3% | 16.3% | ||
| Q2 24 | -57.9% | 16.7% | ||
| Q1 24 | -68.2% | 12.1% |
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | $0.39 | ||
| Q2 25 | $-0.80 | $0.15 | ||
| Q1 25 | $-0.77 | $0.68 | ||
| Q4 24 | $-0.90 | $0.54 | ||
| Q3 24 | $-0.88 | $0.55 | ||
| Q2 24 | $-0.84 | $0.58 | ||
| Q1 24 | $-0.94 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $575.8M |
| Total DebtLower is stronger | $1.5B | $16.0K |
| Stockholders' EquityBook value | $-99.3M | $1.1B |
| Total Assets | $2.0B | $1.8B |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | $575.8M | ||
| Q2 25 | $629.1M | $558.4M | ||
| Q1 25 | $698.6M | $642.2M | ||
| Q4 24 | $525.5M | $640.7M | ||
| Q3 24 | $585.0M | $606.4M | ||
| Q2 24 | $933.7M | $559.9M | ||
| Q1 24 | $1.0B | $521.5M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | $16.0K | ||
| Q2 25 | $1.1B | $19.0K | ||
| Q1 25 | $1.1B | $21.0K | ||
| Q4 24 | $1.1B | $25.0K | ||
| Q3 24 | — | $28.0K | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $2.7M |
| Q4 25 | $-99.3M | — | ||
| Q3 25 | $-354.5M | $1.1B | ||
| Q2 25 | $-305.5M | $1.1B | ||
| Q1 25 | $-250.8M | $1.1B | ||
| Q4 24 | $-139.6M | $1.1B | ||
| Q3 24 | $-60.1M | $1.1B | ||
| Q2 24 | $-1.6M | $1.0B | ||
| Q1 24 | $68.3M | $1.0B |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.3B | $1.8B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.6B | ||
| Q1 24 | $1.7B | $1.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $50.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $25.2M |
| FCF MarginFCF / Revenue | -19.3% | 12.0% |
| Capex IntensityCapex / Revenue | 9.9% | 11.8% |
| Cash ConversionOCF / Net Profit | — | 2.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $64.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | — | ||
| Q3 25 | $-35.4M | $50.1M | ||
| Q2 25 | $-60.3M | $31.5M | ||
| Q1 25 | $-62.7M | $78.5M | ||
| Q4 24 | $-64.5M | $68.4M | ||
| Q3 24 | $-51.1M | $75.1M | ||
| Q2 24 | $-94.0M | $76.5M | ||
| Q1 24 | $-30.3M | $41.5M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | $25.2M | ||
| Q2 25 | $-65.9M | $-29.1M | ||
| Q1 25 | $-67.1M | $43.3M | ||
| Q4 24 | $-83.4M | $25.2M | ||
| Q3 24 | $-55.3M | $50.7M | ||
| Q2 24 | $-99.1M | $56.5M | ||
| Q1 24 | $-37.2M | $-1.8M |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | 12.0% | ||
| Q2 25 | -28.4% | -13.8% | ||
| Q1 25 | -33.0% | 20.4% | ||
| Q4 24 | -41.3% | 11.3% | ||
| Q3 24 | -28.9% | 24.0% | ||
| Q2 24 | -55.9% | 26.0% | ||
| Q1 24 | -22.1% | -0.8% |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | 11.8% | ||
| Q2 25 | 2.4% | 28.7% | ||
| Q1 25 | 2.2% | 16.6% | ||
| Q4 24 | 9.4% | 19.4% | ||
| Q3 24 | 2.2% | 11.6% | ||
| Q2 24 | 2.9% | 9.2% | ||
| Q1 24 | 4.1% | 20.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.19× | ||
| Q2 25 | — | 3.55× | ||
| Q1 25 | — | 1.83× | ||
| Q4 24 | — | 2.02× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
